Back to today’s briefing

Story perspectives

Promising Lorundrostat Treatment Shows 15.4 mmHg Blood Pressure Drop

3/29/2025

48 11

Summary

Story summary

Exciting breakthroughs emerged at the American College of Cardiology meeting as researchers unveiled promising results for lorundrostat, a groundbreaking treatment for uncontrolled hypertension. In a Phase 2 trial, patients saw an impressive 15.4 mmHg drop in systolic blood pressure compared to those on a placebo, paving the way for potential FDA approval in just 12 to 18 months.

1 of 1

Story summary

Exciting breakthroughs emerged at the American College of Cardiology meeting as researchers unveiled promising results for lorundrostat, a groundbreaking treatment for uncontrolled hypertension. In a Phase 2 trial, patients saw an impressive 15.4 mmHg drop in systolic blood pressure compared to those on a placebo, paving the way for potential FDA approval in just 12 to 18 months.